Assessment of HIV-TB co-infection in newly diagnosed HIV positive patients and their correlation with CD4 and viral load
DOI:
https://doi.org/10.18203/2320-6012.ijrms20231628Keywords:
HIV, TB, CD4, VL, GeneXpertAbstract
Background: Human Immunodeficiency Virus (HIV) and Tuberculosis (TB) constitute a major burden of infectious diseases in India. TB is the most common opportunistic infection and a leading cause of death among HIV positive patients. This study was conducted to assess the HIV–TB co-infection in newly diagnosed HIV patients and correlate co-infection with CD4 and viral load (VL).
Methods: A prospective observational study was carried out from January 2021 to June 2022 at ART center of a tertiary care hospital. Screening for TB was done by GeneXpert and Radiology. These patients were monitored for absolute CD4 count by flow cytometer and VL by Real time PCR.
Results: Among 380 newly diagnosed HIV patients screened, 94 (24.70%) had HIV-TB coinfection. Of these, 42 (44.6%) were pulmonary tuberculosis (PTB) and 52 (55.3%) were extrapulmonary tuberculosis (EPTB) of 42 patients with PTB, 31 (73.80%) were microbiologically confirmed by GeneXpert whereas of 52 patients with EPTB, 33 (63.46%) were diagnosed clinically and radio-logically. Of 94 patients, only 55 patients could be followed up further at 6 months. Of 55 patients, 33 (60%) had CD4 count <350 cells/mm3 and 2 (3.6%) had baseline VL≥1000 copies/ml. 46.80% patients completed their anti-tubercular treatment.
Conclusions: EPTB was more as compared to PTB. Co-infection was more with low CD4 counts. Hence, CD4 test can be used as a good immunological marker in co-infection. The study highlights the need of periodic screening of newly diagnosed HIV patients for TB and their monitoring for CD4 and VL.
References
UNAIDS: Global HIV statistics 2021. Available at https://www.unaids.org/en/resources/fact-sheet. Accessed on 20 February 2023.
Global summary of the AIDS epidemic. Geneva: UNAIDS; 2017. Available at https://www.unaids.org/sites/default/files/media_asset/20170720_Data_book_2017_en.pdf. Accessed on 2 February 2023.
CDC: Managing Drug Interactions in the Treatment of HIV-Related Tuberculosis: 2013. Available at https://www.cdc.gov/tb/publications/guidelines/tb_hiv_drugs/introduction.htm. Accessed on 12 February 2023.
National AIDS Control Organization and ICMR-National Institute of Medical Statistics. Available at https://naco.gov.in/. Accessed on 12 February 2023.
WHO. Global Tuberculosis Report 2018. World Health Organization (2018). Available at https://apps.who.int/iris/handle/10665/274453. Accessed on 20 February 2023.
Bruchfeld J, Correia-Neves M, Källenius G. Tuberculosis and HIV Coinfection. Cold Spring Harb Perspect Med. 2015;5(7):a017871.
Global tuberculosis report 2022. Geneva: World Health Organization; 2022. Licence: CC BY-NC-SA 3.0 IGO. Available at https:/ /www.who.int /teams/global-tuberculosis-programme/ tb-reports/ global-tuberculosis-report-2022. Accessed on 20 February 2023.
Whalen C, Horsburgh CR, Hom D, Lahart C, Simberkoff M, Ellner J. Accelerated course of human immunodeficiency virus infection after tuberculosis. Am J Respir Crit Care Med. 1995;151:129-35.
National Technical Guidelines On AntiRetroviral Treatment National AIDS Control Organization Ministry of Health and Family Welfare Government of India, October 2018.
Control CD, Prevention. Guidelines for the Prevention and Treatment of opportunistic infections in HIV-infected adults and adolescents. MMWR. 2009;58(4):1-206.
Kwan CK, Ernst JD. HIV and tuberculosis: A deadly human syndemic. Clin Microbiol Rev. 2011;24:351-76.
Toossi Z, Kizza H, Hirsch C, Edmonds K, Spahlinger T, Hom D, et al. Impact of tuberculosis (TB) on HIV-1 activity in dually infected patients. Clin Exp Immunol. 2001;123(2):233-8.
Toossi Z. Virological and immunological impact of tuberculosis on human immunodeficiency virus type 1 disease. J Infect Dis. 2003;188(8):1146-55.
Lawn SD, Myer L, Edwards D, Bekker LG, Wood R. Short-term and long-term risk of tuberculosis associated with CD4 cell recovery during antiretroviral therapy in South Africa. AIDS. 2009;23(13):1717-25.
Musa BM, Musa B, Muhammed H, Ibrahim N, Musa AG. Incidence of tuberculosis and immunological profile of TB/HIV co-infected patients in Nigeria. Ann Thorac Med. 2015;10(3):185-92.
Fujiwara PI, Dlodlo RA, Ferroussier O, Nakanwagi‑Mukwaya A, Cesari G, Boillot F, et al. Implementing collaborative TB‑HIV activities: A programmatic guide. Paris, France: International Union against Tuberculosis and Lung Disease; 2012;7:87-9.
National AIDS Control Organization (2021). Sankalak: Status of National AIDS Response (Third edition, 2021). New Delhi: NACO, Ministry of Health and Family Welfare, Government of India.
National AIDS Control Organization (2021). National Guidelines for HIV Care and Treatment, 2021. New Delhi: NACO, Ministry of Health and Family Welfare, Government of India.
Tesfaye B, Alebel A, Gebrie A, Zegeye A, Tesema C, Kassie B. The twin epidemics: Prevalence of TB/HIV co-infection and its associated factors in Ethiopia; A systematic review and meta-analysis. PLoS ONE. 2018;13(10):0203986.
Kapadiya DJ, Dave PV, Vadera B, Patel PG, Chawla S, Saxena D. Assessment of Tuberculosis Prevalence in Newly Diagnosed Human Immunodeficiency Virus-Infected Adults Attending Care and Treatment Center in Gujarat, India. Indian J Community Med. 2018;43(3):185-9.
Reddy SG, Ali SY, Khalidi A. Study of infections among human immunodeficiency virus/acquired immunodeficiency syndrome patients in Shadan Hospital, Telangana, India. Indian J Sex Transm Dis. 2016;37:147-50.
Mollel EW, Maokola W, Todd J, Msuya SE, Mahande MJ. Incidence Rates for Tuberculosis Among HIV Infected Patients in Northern Tanzania. Front Public Health. 2019;7:306.
Dahiya N, Bachani D, Das R, Rasania SK. Socio-demoFigureic and clinical profi le of HIV positive patients attending integrated counseling and testing centre of a primary health centre in Delhi. SAARC J Tuber Lung Dis HIV/AIDS. 2017;15:22-6.
Aturaka SO, Abiodun O, Omotola O, Adebimpe WO, Philip Imohi et al.. Prevalence and Correlates of TB and HIV Co-infection among People Living with HIV/AIDs at the DLHM Hospital, Calabar. Am J Health Res. 2017;5:106-9.
Dravid A, Natarajan K, Medisetty M, Gawali R, Mahajan U, Kulkarni M, Saraf C, Ghanekar C, Kore S, Rathod N, Dravid M. Incidence of tuberculosis among HIV infected individuals on long term antiretroviral therapy in private healthcare sector in Pune, Western India. BMC Infect Dis. 2019;19(1):714.
Chandra NM, Babu RA, Prasad DTS, Devulapalli M, Banu SSK, Avanthi B, et al. Epidemiological surveillance of tuberculosis among HIV/AIDS seropositive individuals attending ART center at a tertiary care teaching hospital. Int J Community Med Public Health. 2017;4:2816-24.
Picon PD, Bassanesi SL, Caramori ML, Ferreira RL, Jarczewski CA, Vieira PR. Risk factors for recurrence of tuberculosis. J Bras Pneumol. 2007;33(5):572-8.
Magna M, Sitikantha N. Prevalence of HIV infection among tuberculosis patients in Eastern India. J Infect Public Health. 2013;6:358-62.
Kamath R, Sharma V, Pattanshetty S, Hegde MB, Chandrasekaran V. HIV-TB coinfection: Clinico-epidemiological determinants at an antiretroviral therapy center in Southern India. Lung India. 2013;30(4):302-6.
Siddeswari R, Amaravathi KS, Rao NS, Rewari B, Kumar P. HIV/AIDS-tuberculosis (pulmonary and extra pulmonary) co-infection: CD4 correlation. Int J Res Med Sci. 2016;28:1035-9.
Chandwani J, Soni P, Parihar G, Meena C. Evaluation of CD4 Cell Count and its Associating Factors-In HIV-TB Co-Infection. Int J Curr Microbiol App Sci. 2017;6:747-52.
Getaneh T, Negesse A, Dessie G, Desta M. The impact of tuberculosis co-infection on virological failure among adults living with HIV in Ethiopia: A systematic review and meta-analysis. J Clin Tuberc Other Mycobact Dis. 2022;27:100310.
